160 related articles for article (PubMed ID: 37900840)
1. The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with
Badran A; Steele C; Alquaydheb H; Ba Theeb A; Bawazir A; Elshenawy MA; Atallah JP
Case Rep Oncol; 2023; 16(1):746-752. PubMed ID: 37900840
[TBL] [Abstract][Full Text] [Related]
2. Sclerosing epithelioid fibrosarcoma associated with WRN gene variant presenting as chronic dyspnea and pathologic cervical fracture: a case report and review of the literature.
Phan AT; Ghantarchyan H; Khosravi C; Maknouni B; Bhagat A; Chen J; Ibrahim A; Hasan M
J Med Case Rep; 2023 Dec; 17(1):517. PubMed ID: 38104125
[TBL] [Abstract][Full Text] [Related]
3. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
4. ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report.
Xu X; Li H; Peng K; Yu Y; Chen L; Fang Y; Sun Y; Hou Y; Liu T
Oncol Lett; 2019 Feb; 17(2):2370-2376. PubMed ID: 30675302
[TBL] [Abstract][Full Text] [Related]
5. Primary sclerosing epithelioid fibrosarcoma of the sacrum: a case report and review of the literature.
Chow LT; Lui YH; Kumta SM; Allen PW
J Clin Pathol; 2004 Jan; 57(1):90-4. PubMed ID: 14693846
[TBL] [Abstract][Full Text] [Related]
6. FUS rearrangements are rare in 'pure' sclerosing epithelioid fibrosarcoma.
Wang WL; Evans HL; Meis JM; Liegl-Atzwanger B; Bovee JV; Goldblum JR; Billings SD; Rubin BP; López-Terrada D; Lazar AJ
Mod Pathol; 2012 Jun; 25(6):846-53. PubMed ID: 22388756
[TBL] [Abstract][Full Text] [Related]
7. Needle tract seeding of a sclerosing epithelioid fibrosarcoma in a biopsy tract: a case report.
Kawai M; Miwa S; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Taniguchi Y; Araki Y; Yonezawa H; Nojima T; Tsuchiya H
BMC Musculoskelet Disord; 2023 Jun; 24(1):454. PubMed ID: 37270505
[TBL] [Abstract][Full Text] [Related]
8. Oral and maxillofacial sclerosing epithelioid fibrosarcoma: report of five cases.
Folk GS; Williams SB; Foss RB; Fanburg-Smith JC
Head Neck Pathol; 2007 Sep; 1(1):13-20. PubMed ID: 20614275
[TBL] [Abstract][Full Text] [Related]
9. Sclerosing epithelioid fibrosarcoma as a rare cause of ascites in a young man: a case report.
Smith PJ; Almeida B; Krajacevic J; Taylor B
J Med Case Rep; 2008 Jul; 2():248. PubMed ID: 18657268
[TBL] [Abstract][Full Text] [Related]
10. MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement.
Doyle LA; Wang WL; Dal Cin P; Lopez-Terrada D; Mertens F; Lazar AJ; Fletcher CD; Hornick JL
Am J Surg Pathol; 2012 Oct; 36(10):1444-51. PubMed ID: 22982887
[TBL] [Abstract][Full Text] [Related]
11. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
12. Sclerosing epithelioid fibrosarcoma of the kidney: clinicopathologic and molecular study of a rare neoplasm at a novel location.
Ohlmann CH; Brecht IB; Junker K; van der Zee JA; Nistor A; Bohle RM; Stöckle M; Metzler M; Hartmann A; Agaimy A
Ann Diagn Pathol; 2015 Aug; 19(4):221-5. PubMed ID: 25990776
[TBL] [Abstract][Full Text] [Related]
13. The hundredth case of sclerosing epithelioid fibrosarcoma (SEF).
Monarca C; Fino P; Rizzo MI; Palmieri A; Tarallo M; Scuderi N
Ann Ital Chir; 2013; 84(3):315-8. PubMed ID: 23856987
[TBL] [Abstract][Full Text] [Related]
14. A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.
Sekimizu M; Osumi T; Fukano R; Koga Y; Kada A; Saito AM; Mori T
Acta Med Okayama; 2018 Aug; 72(4):431-436. PubMed ID: 30140094
[TBL] [Abstract][Full Text] [Related]
15. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
16. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
[TBL] [Abstract][Full Text] [Related]
17. [Pleural metastases of sclerosing epithelioid fibrosarcoma].
Decroisette C; Melloni B; Moldovan D; Gazaille V; Fermeaux V; Bertin F; Bonnaud F
Rev Pneumol Clin; 2006 Jun; 62(3):179-82. PubMed ID: 16840996
[TBL] [Abstract][Full Text] [Related]
18. Sclerosing Muc-4-positive sarcoma with glandular differentiation resembling sclerosing epithelioid fibrosarcoma.
Chebib I; Desphande V; Nielsen GP
Int J Surg Pathol; 2015 Apr; 23(2):144-8. PubMed ID: 25411219
[TBL] [Abstract][Full Text] [Related]
19. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
Front Oncol; 2022; 12():761558. PubMed ID: 35237506
[TBL] [Abstract][Full Text] [Related]
20. Metastatic Sclerosing Epithelioid Fibrosarcoma in Bone Marrow.
Asakra R; Zaidi S; Thway K
Int J Surg Pathol; 2017 Dec; 25(8):702-704. PubMed ID: 28697683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
